Welcome to our dedicated page for Akari Therapeutics Plc SEC filings (Ticker: AKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering whether nomacopan hit its clinical endpoints or how much cash Akari has left to fund trials? Investors comb Akari Therapeutics filings for exactly these answers. From fresh Phase II data tucked into an 8-K to detailed R&D spend in the quarterly 10-Q, each document shapes the outlook for this orphan-disease biotech.
Stock Titan keeps every disclosure in one place and makes them readable. Our AI converts the 200-page annual report into plain language, surfaces section-by-section highlights, and links directly to the numbers you need. Searching for “Akari Therapeutics insider trading Form 4 transactions” or real-time alerts on executive stock moves? We tag each Form 4 the moment it hits EDGAR and show patterns across time. Need the “Akari Therapeutics quarterly earnings report 10-Q filing” or an “Akari Therapeutics proxy statement executive compensation” breakdown? One click delivers AI-generated context alongside the original PDF.
- Track trial milestones via “Akari Therapeutics 8-K material events explained”
- Get cash-runway metrics from the latest “Akari Therapeutics earnings report filing analysis”
- Receive instant alerts on “Akari Therapeutics Form 4 insider transactions real-time”
Whether you’re understanding Akari Therapeutics SEC documents with AI or need the “Akari Therapeutics annual report 10-K simplified”, our platform delivers clarity. Stop downloading bulky files; start focusing on the clinical and financial signals that move AKTX.
Akari Therapeutics (AKTX) launched a primary registered direct offering of 3,125,000 ADSs at $0.80 per ADS, for gross proceeds of $2.5 million. The deal is on a best efforts basis via Ladenburg Thalmann, with no minimum. The company estimates net proceeds of approximately $1.8 million after placement agent fees and offering expenses, and expects delivery around October 16, 2025, subject to customary closing conditions.
In a concurrent private placement, Akari is issuing 3,125,000 Series E warrants and 3,125,000 Series F warrants, each exercisable for one ADS at $0.98 per ADS, beginning on the Shareholder Approval Date. These warrants and the ADSs issuable upon exercise are not registered here. The company plans to file a resale registration statement within 30 days after closing. Akari intends to use net proceeds for working capital, general corporate purposes, and continued R&D, including generating differentiated data on its novel ADC payload. The company states that, together with existing cash, funds are expected to meet capital needs into December 2025. The filing notes expected immediate and substantial dilution of approximately $1.44 per ADS to new purchasers.
Akari Therapeutics entered a registered direct offering of 3,125,000 ADSs at $0.80 per ADS, for expected $2.5 million in aggregate gross proceeds, subject to customary closing conditions. The ADS sale is a takedown from Akari’s effective Form F-3 shelf.
Concurrently, the company issued Series E and Series F warrants in a private placement, each exercisable for up to 3,125,000 ADSs at an exercise price of $0.98 per ADS. Both series become exercisable on the effective date of shareholder approval; Series E carries a five-year term and Series F a thirty‑month term. Akari will file a resale registration for the warrant shares within 30 days of closing and will call a shareholder meeting within 60 days to seek approval, then every 40 days until obtained or the warrants expire.
Ladenburg Thalmann is placement agent, entitled to a 7.2% fee, 0.5% management fee, up to $75,000 expense allowance, and Placement Agent Warrants to purchase 125,000 ADSs at $1.00 per ADS (five‑year term). The purchase agreement includes a 30‑day issuance/registration standstill and a one‑year prohibition on variable rate transactions, in each case with customary exceptions.
Akari Therapeutics (AKTX) furnished an 8-K announcing a $2.5 million registered direct offering. The company disclosed, under Item 7.01 (Regulation FD), that it issued a press release titled “Akari Therapeutics Announces $2.5 Million Registered Direct Offering.” The press release is included as an exhibit and the furnished information is not deemed filed under the Exchange Act.
Akari’s American Depositary Shares, each representing 2,000 ordinary shares, trade on Nasdaq under the symbol AKTX. The filing lists the date of the earliest event as October 15, 2025.
Akari Therapeutics plc provides fragmentary financial and offering details in this S-1 registration extract. The company discloses operating expense line items including general and administrative amounts shown as 9,664 and 3,661 with a combined presentation of 13,325, and merger-related costs of 3,273. Selected other income (expense) items include interest income of 8, multiple interest expense entries (including (244) and (3,130)), a change in fair value of warrant liabilities of 2,085, and various gains such as a gain on extinguishment of lease termination of 4,305 and a gain on settlement of derivative liability of 4,285. Comprehensive (loss) income entries show Net (loss) income of $(19,791), offset in other columns by 272 and 43, producing a combined (19,476) figure. Weighted-average shares used in per-share calculations are reported across columns including 23,888,010,485, 21,919,309,049, and a total of 45,807,319,534. Estimated offering expenses of issuance are itemized as $34,000 accounting, $60,000 legal, $1,000 miscellaneous, totaling $97,000. The filing also lists numerous exhibits and securities agreements, including warrant and deposit agreement forms.
Akari Therapeutics plc (AKTX) insider Form 4: Gaslightwala Abizer, listed as both CEO and a director, reported multiple open-market purchases of the company’s American Depositary Shares in August 2025. Each American Depositary Share (ADS) represents 2,000 ordinary shares. On 08/21/2025 he acquired 10,000 ADS at a weighted average price of $0.94 increasing his holdings to 287,574 ADS. On 08/22/2025 he acquired 8,000 ADS at $0.93 (holdings: 295,574 ADS), and on 08/25/2025 he acquired 3,000 ADS at $0.90 (holdings: 298,574 ADS). The filing is signed by an attorney-in-fact on 08/29/2025.
Akari Therapeutics plc disclosed that its Chairman, Dr. Hoyoung Huh, purchased a Note with a $1,250,000 principal amount for a purchase price of $1,000,000. The purchase was satisfied with $162,567 in cash and by cancelling $837,433 of outstanding principal and accrued interest under a senior secured promissory note previously issued to him by the companys subsidiary, Peak Bio Inc. The company and Dr. Huh executed a Loan Cancellation and Exchange Agreement on August 7, 2025, to effect the cancellation; the full agreement is filed as Exhibit 10.1 to the Form 8-K.
FAQ
What is the current stock price of Akari Therapeutics Plc (AKTX)?
What is the market cap of Akari Therapeutics Plc (AKTX)?
